Chemistry:Enarodustat
From HandWiki
Short description: Chemical compound
![]() | |
Clinical data | |
---|---|
Trade names | Enaroy |
Other names | JTZ-951 |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C17H16N4O4 |
Molar mass | 340.339 g·mol−1 |
3D model (JSmol) | |
| |
|
Enarodustat (development code JTZ-951; brand name Enaroy) is a drug used for the treatment of anemia, especially when associated with chronic kidney disease (CKD). Enarodustat functions as a inhibitor of hypoxia inducible factor-proly hydroxylase (HIF-PH).[1]
The drug was approved in September 2020 in Japan for anemia associated with CKD[2] and is currently in clinical development in the United States and South Korea.[3] The drug is being developed by Japan Tobacco and JW Pharmaceutical.[4]
References
- ↑ "HIF-α Prolyl Hydroxylase Inhibitors and Their Implications for Biomedicine: A Comprehensive Review". Biomedicines 9 (5): 468. April 2021. doi:10.3390/biomedicines9050468. PMID 33923349.
- ↑ "JT Receives Manufacturing and Marketing Approval of ENAROY Tablets 2mg・4mg for the Treatment of Anemia Associated with Chronic Kidney Disease in Japan" (PDF) (Press release). September 25, 2020.
- ↑ "Enarodustat: First Approval". Drugs 81 (1): 169–174. January 2021. doi:10.1007/s40265-020-01444-3. PMID 33320297.
- ↑ "Enarodustat - Japan Tobacco". Adis Insight. https://adisinsight.springer.com/drugs/800035317.
![]() | Original source: https://en.wikipedia.org/wiki/Enarodustat.
Read more |